Dr. Pandya is a passionate Oncologist who brings nearly 20 years of oncology drug development expertise to Atavistik Bio. She most recently served as Vice President, Clinical Development and Global Head of late-stage oncology at Servier Pharmaceuticals where she led all late-stage clinical development programs in oncology and hematology and played an integral role in corporate business development and portfolio strategy. Before joining Servier, Dr. Pandya led the clinical development of the mutant isocitrate dehydrogenase (IDH) inhibitor portfolio at Agios Pharmaceuticals, including Tibsovo and Voranigo, which were acquired by Servier in 2021. In this role, she also designed pivotal Phase 3 programs and oversaw multiple global drug approvals across a range of oncology indications including AML, MDS, Cholangiocarcinoma, and Glioma. Earlier in her career, she focused on early-phase development at Acceleron Pharma.
Dr. Pandya earned her MD from Tufts University School of Medicine and completed her residency in internal medicine and fellowship in hematology/oncology and held a clinical practice at Beth Israel Deaconess Medical Center. She also serves on the Board of Directors of MOMA Therapeutics.